Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Timothy SpelmanWilliam L HerringYuanhui ZhangMichael TempestIsobel PearsonUlrich FreudensprungCarlos AcostaThibaut DortRobert HydeEva HavrdovaDana HorakovaMaria TrojanoGiovanna De LucaAlessandra LugaresiGuillermo IzquierdoPierre GrammondPierre DuquetteRaed AlroughaniEugenio PucciFranco GranellaJeannette Lechner-ScottPatrizia SolaDiana FerraroFrancois Grand'MaisonMurat TerziCsilla RozsaCavit BozRaymond HuppertsVincent Van PeschCelia Oreja-GuevaraAnneke van der WaltVilija G JokubaitisTomas KalincikHelmut Butzkuevennull nullPublished in: PharmacoEconomics (2021)
This novel real-world analysis suggests a clinical benefit for therapy escalation to natalizumab versus fingolimod based on comparative effectiveness results, translating to higher QALYs and lower costs for UK patients inadequately responding to BRACETD.